Our portfolio company Mekonos has formally closed its US$4.6mil capital raise, led by Novartis with participation from a number of US institutional VC Funds as well as Matū Fund. The capital will allow Mekonos to accelerate the development of System-on-Chip ex vivo gene engineering, with a clear path to market.

Read more here: https://www.prnewswire.com/news-releases/mekonos-raises-4-6m-for-its-gene-engineering-platform-301179095.html